40 related articles for article (PubMed ID: 33242523)
21. Production of human parvovirus 4 VP2 virus-like particles in yeast and their evaluation as an antigen for detection of virus-specific antibodies in human serum.
Tamošiūnas PL; Simutis K; Kodzė I; Firantienė R; Emužytė R; Petraitytė-Burneikienė R; Zvirblienė A; Sasnauskas K
Intervirology; 2013; 56(5):271-7. PubMed ID: 23941824
[TBL] [Abstract][Full Text] [Related]
22. Immunogenicity of virus-like particles containing modified goose parvovirus VP2 protein.
Chen Z; Li C; Zhu Y; Wang B; Meng C; Liu G
Virus Res; 2012 Oct; 169(1):306-9. PubMed ID: 22940567
[TBL] [Abstract][Full Text] [Related]
23. Self-assembly of virus-like particles of canine parvovirus capsid protein expressed from Escherichia coli and application as virus-like particle vaccine.
Xu J; Guo HC; Wei YQ; Dong H; Han SC; Ao D; Sun DH; Wang HM; Cao SZ; Sun SQ
Appl Microbiol Biotechnol; 2014 Apr; 98(8):3529-38. PubMed ID: 24413974
[TBL] [Abstract][Full Text] [Related]
24. Potent neutralization activity against type O foot-and-mouth disease virus elicited by a conserved type O neutralizing epitope displayed on bovine parvovirus virus-like particles.
Chang J; Zhang Y; Yang D; Jiang Z; Wang F; Yu L
J Gen Virol; 2019 Feb; 100(2):187-198. PubMed ID: 30547855
[TBL] [Abstract][Full Text] [Related]
25. Generation in yeast and antigenic characterization of hepatitis E virus capsid protein virus-like particles.
Simanavicius M; Tamosiunas PL; Petraityte-Burneikiene R; Johne R; Ulrich RG; Zvirbliene A; Kucinskaite-Kodze I
Appl Microbiol Biotechnol; 2018 Jan; 102(1):185-198. PubMed ID: 29143081
[TBL] [Abstract][Full Text] [Related]
26. Construction and characterization of virus-like particles: a review.
Zeltins A
Mol Biotechnol; 2013 Jan; 53(1):92-107. PubMed ID: 23001867
[TBL] [Abstract][Full Text] [Related]
27. Parvovirus glycan interactions.
Huang LY; Halder S; Agbandje-McKenna M
Curr Opin Virol; 2014 Aug; 7():108-18. PubMed ID: 25047752
[TBL] [Abstract][Full Text] [Related]
28. Antigenicity study of the yeast-generated human parvovirus 4 (PARV4) virus-like particles.
Lazutka J; Simutis K; Matulis P; Petraitytė-Burneikienė R; Kučinskaitė-Kodzė I; Simanavičius M; Tamošiunas PL
Virus Res; 2021 Jan; 292():198236. PubMed ID: 33242523
[TBL] [Abstract][Full Text] [Related]
29. Parvovirus Capsid-Antibody Complex Structures Reveal Conservation of Antigenic Epitopes Across the Family.
Emmanuel SN; Mietzsch M; Tseng YS; Smith JK; Agbandje-McKenna M
Viral Immunol; 2021; 34(1):3-17. PubMed ID: 32315582
[TBL] [Abstract][Full Text] [Related]
30. Therapeutic Potential of Engineered Virus-like Particles of Parvovirus B19.
Sánchez-Moguel I; Montiel C; Bustos-Jaimes I
Pathogens; 2023 Aug; 12(8):. PubMed ID: 37623967
[TBL] [Abstract][Full Text] [Related]
31. PARV4: an emerging tetraparvovirus.
Matthews PC; Malik A; Simmons R; Sharp C; Simmonds P; Klenerman P
PLoS Pathog; 2014 May; 10(5):e1004036. PubMed ID: 24789326
[No Abstract] [Full Text] [Related]
32. Human parvovirus 4 'PARV4' remains elusive despite a decade of study.
Matthews PC; Sharp C; Simmonds P; Klenerman P
F1000Res; 2017; 6():82. PubMed ID: 28184291
[TBL] [Abstract][Full Text] [Related]
33.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
34.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [New Search]
